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Acute coronary syndromeBackgrounds: Glycero-lysophospholipids (glycero-LPLs), which are known to exert potent biological activities,
have been demonstrated to be secreted from activated platelets in vitro; however, their association with platelet
activation in vivo has not been yet elucidated. In this study, we investigated the correlations between the blood
levels of each glycero-LPL and serotonin, a biomarker of platelet activation, in human subjects to elucidate the
involvement of platelet activation in glycero-LPLs in vivo.
Methods and Results: We measured the plasma serotonin levels in 141 consecutive patients undergoing
coronary angiography (acute coronary syndrome, n = 38; stable angina pectoris, n = 71; angiographically
normal coronary arteries, n = 32) and investigated the correlations between the plasma levels of serotonin
and glycero-LPLs. The results revealed the existence of a speciﬁc and signiﬁcant association between the
plasma serotonin and plasma lysophosphatidylserine (LysoPS) levels. On the contrary, regular aspirin
intake failed to affect the plasma LysoPS levels despite the fact that the plasma lysophosphatidic acid,
lysophosphatidylethanolamine, lysophosphatidylglycerol, and lysophosphatidylinositol levels were lower
in those who had taken aspirin regularly.
Conclusion:We found a speciﬁc positive correlation between the blood levels of serotonin and LysoPS, a new
lipid mediator. Thus, LysoPS might be speciﬁcally involved in strong platelet activation, which is associated
with the release of serotonin.
General Signiﬁcance: Our present results suggest the possible involvement of LysoPS in the pathogenesis of
atherosclerotic diseases.
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. This is an open access article under1. Background
Abnormal platelet activation is involved in the pathogenesis of
several fatal diseases, including acute coronary syndrome (ACS),
the incidence of which continues to increase worldwide, threaten-
ing human health. Therefore, it would be desirable to identify
novel biomarkers reﬂecting platelet activation to develop as new
targets for the diagnosis, prevention and treatment of such diseases.
While many candidate molecules have been proposed, glycero-
lysophospholipids (glycero-LPLs) are among the promising targets.
Glycero-LPL is composed of a glycerol backbone with one fatty-
acid chain and one hydrophilic compartment, according to whichthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. The plasma concentrations of serotonin in the subjects who underwent coronary
angiography. The plasma serotonin levels in the NCA, SAP and ACS groups.
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lysophosphatidylcholine (LysoPC), lysophosphatidylethanolamine
(LysoPE), lysophosphatidylglycerol (LysoPG), lysophosphatidylinositol
(LysoPI), and lysophosphatidylserine (LysoPS) [1,2]. At present, they
are drawing much attention, since several speciﬁc receptors against
glycero-LPLs have recently been identiﬁed [3,4].
Among the glycero-LPLs, LysoPA has been most investigated
from the aspect of involvement in platelet activation; LysoPA has
been demonstrated to be secreted from activated platelets [5,6]
and to induce platelet shape changes, platelet-monocyte aggregation
and further aggregation of platelets [7–9]. Furthermore, minor
glycero-LPLs other than LysoPA, such as LysoPS [10], LysoPC, LysoPE
[11] and LysoPI [12] have also been demonstrated to be secreted
from activated platelets in vitro, although their physiological
roles in platelet activation and the consequent pro-atherosclerotic
responses have not yet been fully elucidated.
Recently, we reported that the plasma glycero-LPL levels were sig-
niﬁcantly increased in subjects with ACS, but not in those with stable
angina pectoris (SAP), as compared to the levels in subjects with angio-
graphically normal coronary arteries (NCA) [13]. Although based on the
ﬁndings from previous in vitro experiments [5,6,10–12], the source of
the elevated glycero-LPL levels in subjectswithACSmight be speculated
to be activated platelets, it remains to bedeﬁnitively elucidatedwhether
the glycero-LPLs are actually derived from platelets in vivo and whether
any differences exist among the glycero-LPLs in the pathways by which
they are secreted from activated platelets.
In this study, we measured the levels of serotonin as a biomarker of
platelet activation in plasma samples [14–16] obtained from the sub-
jects for our previous study and investigated the correlations between
the plasma levels of the glycero-LPLs and this thrombotic biomarker.
2. Methods
2.1. Samples from patients who underwent coronary angiography and
measurement of the LPL species
The collection of samples from subjects who underwent coronary
angiography in our previous study has been described in earlier reports
[13,17]. The present study was conducted with the approval of the
ethics review committee at Juntendo University Hospital, all the partic-
ipants signed informed consent forms, and the study was registered in
the UMIN protocol registration system (#UMIN000002103). This
study was also approved by the institutional review boards of both the
University of Tokyo and the Juntendo University School of Medicine.
Arterial blood samples were obtained from the arterial sheaths of all
the patients in the angiography room prior to the coronary angiography
procedures. The blood samples were collected directly into glass
vacutainer tubes with or without EDTA to obtain plasma and serum
samples, respectively. The samples were immediately placed on ice.
The anticoagulated samples were then centrifuged at 1000 ×g for
10 min, and the supernatant comprising the plasma was carefully
collected, avoiding contamination with the cell components. Whole
blood samples collected in tubes not containing EDTA-2Na were left to
clot, and the serum was separated by centrifugation at 1000 ×g for
10 min. Both the plasma and serum samples were stored in aliquots
at−80 °C, and subjected to one freeze–thaw cycle before themeasure-
ment of the LPLs and to two freeze–thaw cycles before the measure-
ment of serotonin. Quantiﬁcation of the glycero-LPLs was performed
by LC-MS/MS, as previously described [13,18].
2.2. Measurement of plasma serotonin
The plasma serotonin was separated by HPLC with a column-
switching system and was speciﬁcally converted into a ﬂuorescent
derivative with benzylamine for convenience of detection, as described
previously [19,20].2.3. Measurement of the serum phosphatidylserine-speciﬁc phospholipase
A1 (PS-PLA1) levels
The PS-PLA1 antigen levels in the serum were determined using a
two-site immunoenzymetric assay with a PS-PLA1 assay reagent and
the TOSOH AIA system (TOSOH, Tokyo, Japan) [21].
2.4. Statistical analysis
All the data were statistically analyzed using SPSS (Chicago, IL). The
results were expressed asmean± SD. Comparison between two groups
was carried out using the Mann–Whitney U test, while that among
three groups was conducted using the Kruskal–Wallis test followed by
the Games Howell test as a post-hoc test, since normality or equality
of variance was rejected by the Kolmogorov–Smirnov test or the
Levene test for most of the parameters or analyses. Correlations were
determined using the Spearman correlation test. P b 0.05 was regarded
as denoting statistical signiﬁcance in all the analyses.
3. Results
3.1. Plasma serotonin was not signiﬁcantly elevated in subjects with ACS
The basic characteristics and plasma glycero-LPL levels of the three
groups of subjects (NCA, SAP, and ACS) are described in the previous
reports [13,17]. As shown in Fig. 1, no signiﬁcant elevation of the plasma
serotonin level was observed in the ACS patients, although after the
values deviating from the−3 S.D. to +3 S.D. range were eliminated,
the plasma serotonin levels were found to be signiﬁcantly increased in
the ACS group (NCA: 53.3 ± 41.8 nmol/L, SAP: 81.2 ± 60.7 nmol/L,
and ACS: 90.2±74.5 nmol/L). In this study,we performed the following
analyses using all the data including the outliers.
3.2. Plasma serotonin showed a signiﬁcant positive correlation with the
plasma LysoPS
To investigate whether glycero-LPLs are actually secreted from
activated platelets in vivo, as reported from in vitro studies, andwhether
any differencesmight exist among the plasma levels of the glycero-LPLs,
we next compared the plasma level of each glycero-LPLwith the plasma
serotonin level. Interestingly, the plasma serotonin level was found to
be speciﬁcally and signiﬁcantly correlated with the plasma level of
LysoPS (Fig. 2A, r = 0.365, P b 0.001), but not with the plasma levels
of the other glycero-LPLs, including LysoPA. When the data analysis
Fig. 2.Correlations between theplasma levels of serotonin and the glycero-LPLs. The correlation between theplasma levels of serotonin and the glycero-LPLs levels in all subjects (A) and in
the subjects with ACS (B).
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correlation between the plasma serotonin and LysoPS levels was again
observed (ACS [n = 38]: Fig. 2B, r = 0.370, P = 0.022; SAP [n = 71],
r = 0.410, P b 0.01), while no signiﬁcant correlation was obtained in
NCA group.
Since we determined the plasma glycero-LPL levels by LC-MS/MS,
we could also obtain the plasma concentrations of each molecular
species of the glycero-LPLs (14:0, 16:0, 16:1, 18:0, 18:1, 18:2, 18:3,
20:3, 20:4, 20:5, 22:5, and 22:6). Therefore, we next compared the
plasma levels of each molecular species of the glycero-LPLs with the
plasma serotonin. As shown in Table 1, the plasma levels of 18:0, 18:2,
20:5 and 22:6 LysoPS, but not of any of the other molecular species
of the glycero-LPLs (except for 22:6 LysoPE, which showed a weakcorrelation [r = 0.187, P= 0.027]), were signiﬁcantly correlated with
the plasma serotonin level.
3.3. Regular intake of aspirin had no inﬂuence on the plasma LysoPS levels
In this study, 76 of the 141 subjects were regularly taking aspirin
[17], although even those subjects who had not been taking aspirin
regularly took aspirin before they entered the catheter lab. Since aspirin
attenuates the activation of platelets, we next investigated the inﬂuence
of regular aspirin intake on the plasma glycero-LPL levels. The results
revealed that regular intake of aspirin had no effect on the plasma
serotonin levels (Fig. 3A). On the other hand, in regard to the levels of
the glycero-LPLs, the plasma LysoPA, LysoPE, LysoPG and LysoPI levels
Table 1
Correlation between the plasma serotonin level and plasma levels of the glycero-LPL
species.
Molecular species LysoPA LysoPC LysoPE LysoPG LysoPI LysoPS
14:0 0.124 0.106 0.102 −0.008 −0.087 −0.064
16:0 −0.041 0.019 −0.031 0.142‡ 0.062 −0.058
16:1 0.031 0.040 −0.007 0.103 0.078 0.114
18:0 0.029 0.040 0.009 0.089 −0.004 0.330⁎
18:1 0.044 0.059 0.035 0.096 0.105 0.159‡
18:2 0.017 0.053 0.112 0.103 0.089 0.211†
18:3 0.051 0.063 −0.058 0.032 0.034 −0.046
20:3 0.035 0.084 0.083 0.010 0.085 0.063
20:4 0.148‡ 0.042 0.124 0.107 0.113 0.260
20:5 −0.022 0.061 0.099 −0.062 0.092 0.203†
22:5 0.041 0.137 0.084 0.008 0.097 0.067
22:6 0.119 0.132 0.187† 0.059 0.044 0.210†
Correlation between the plasma serotonin level and plasma levels of the glycero-
LPL species.
The Spearman r value is expressed.
⁎ P b 0.01.
† P b 0.05.
‡ P b 0.10.
Fig. 3. Effects of regular aspirin intake on the plasma glycero-LPL levels. The plasma serotonin
aspirin regularly.
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LysoPC and LysoPS remained unaffected (Fig. 3B–G). We speculate that
the plasma LysoPC level might not be modulated by regular intake of
aspirin, because the plasma LysoPC level is several hundred μM even
in normal subjects. On the other hand, the reason for the absence of
any relation between the plasma LysoPS and regular aspirin intake
remains to be resolved.3.4. Serum PS-PLA1 levels showed signiﬁcant correlation with the plasma
LysoPS levels only in ACS group
Although the biosynthetic pathway of LysoPS in vivo has not yet
been clearly elucidated, PS-PLA1 has been assumed as the enzyme
catalyzing the production of LysoPS utilizing phosphatidylserine (PS)
as the substrate [21–23]. Therefore, we also measured the serum
PS-PLA1 level in this study with the assay we had constructed [21].
Considering that recombinant PS-PLA1 concentration is well associated
with the activity of PS-PLA1 in vitro [22], the antigen level of PS-PLA1
likely reﬂects the activity of PS-PLA1, although measuring the activityand glycero-LPL levels in the subjects who had (ASA [+]) and had not (ASA [−]) taken
Fig. 4.Correlation between the serumPS-PLA1 and plasma LysoPS levels. (A) SerumPS-PLA1 levels in theNCA, SAP andACS groups. (B) Correlation between the serumPS-PLA1 and plasma
LysoPS levels in all the subjects. (C) Correlation between the serum PS-PLA1 and plasma LysoPS levels separately in NCA, SAP, and ACS groups.
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no signiﬁcant differences in the serum PS-PLA1 level among the NCA,
SAP and ACS groups, and no signiﬁcant correlation between the serum
PS-PLA1 and plasma LysoPS levels. When the subjects were conﬁned
to ACS, however, the signiﬁcant correlation between the serum
PS-PLA1 and plasma LysoPS levels was observed (Fig. 4C). These
results suggest that PS-PLA1 might not determine the plasma LysoPS
level in a steady state but that PS-PLA1 somehow affected the plasma
LysoPS level in ACS.
4. Discussion
Platelet activation is one of the events responsible for the develop-
ment of ACS and is also known to be involved in the subsequent
pro-atherosclerotic responses, such as further activation of platelets,
migration of inﬂammatory cells, induction of inﬂammatory cytokines,
and so on [24,25]. Recently, glycero-LPLs, such as LysoPA, have emerged
as novel bioactive lipids, and are proposed as one of the new targets for
atherosclerotic diseases [26]. Based on a recent study, we reported that
the plasma levels of the glycero-LPLs are increased in subjects with ACS
[13]; however, it remained unknown whether activated platelets are
involved in the elevation of the plasma glycero-LPLs in vivo andwhether
any differences might exist among the glycero-LPLs in the pathways by
which their levels increased.
In this study, we measured the plasma serotonin level and investi-
gated the correlations between the plasma levels of glycero-LPLs and
serotonin, to determine if a speciﬁc association might exist between
any of the glycero-LPLs and platelet activation in vivo. We observed
that plasma serotonin showed a speciﬁc signiﬁcant positive correlation
with the plasma LysoPS (Fig. 2), but not with the plasma levels of any of
the other glycero-LPLs. Considering that rather strong stimulation is
needed for platelets to secrete serotonin [27,28], it is possible that the
strong platelet activation associated with the release of serotonin
might be involved in the generation of LysoPS.
Contrary to the speciﬁc positive correlation between the plasma
serotonin and LysoPS, the plasma concentrations of LysoPA, LysoPE,
LysoPG and LysoPI were lower in those who took aspirin regularly(Fig. 3B, D, E, F), suggesting that activation of platelets was somehow
involved in the release of these glycero-LPLs. In this study, neither
the plasma serotonin levels (Fig. 3A) nor the plasma LysoPS levels
(Fig. 3G) were lower in those who took aspirin regularly, whereas in a
previous in vitro experiment, aspirin reportedly attenuated the release
of serotonin from platelets [29]. One possible explanation was that at
the point of collecting blood samples, those subjects who had not
been taking aspirin regularly took rather high-dose of aspirin before
they entered the catheter lab. Therefore, this different timing of aspirin
intake between those who had taken aspirin regularly and those had
not might make the interpretation difﬁcult. In any case, we can safely
conclude that the dynamism of LysoPS might be somehow different
from the other glycero-LPLs based on the analysis on the inﬂuence of
regular aspirin intake on glycero-LPLs.
One possible mechanism underlying the positive correlation be-
tween the plasma serotonin and LysoPS levels might involve PS-PLA1
and its substrate, PS. At present, production of LysoPS from PS is
believed to be catalyzed by PS-PLA1 [21–23]. In the resting state, PS is
localized on the inner side of plasma membrane [30,31] while PS-
PLA1 is not expressed in human platelets [23]. Therefore PS is not acces-
sible to PS-PLA1 in the circulation.When platelets are strongly activated,
however, this membrane asymmetry is lost and PS can be exposed ex-
tracellularly to the plasma/serum milieu in the blood [32]. Moreover,
strongly activated platelets secrete PS-containing microparticles into
the circulation [32,33]. Taken together, when platelets are so strongly
activated that they secrete serotonin, PS-PLA1 can access its substrate,
PS, shifting to the outer membrane of the platelets or residing on
microparticles, to produce LysoPS. Regarding the role of PS-PLA1 in
determining the plasma LysoPS, we obtained their signiﬁcant positive
correlation in ACS group, but not in NCA or SAP group (Fig. 4C). This
result suggests that the plasma LysoPS levels might increase to a greater
degree in those who had higher PS-PLA1 in circulation only in the
condition where the substrate PS is accessible to PS-PLA1, such as ACS.
Although PS-PLA1 might be somehow involved in the production of
LysoPS, other pathways independent of PS-PLA1 might exist, since we
have observed the signiﬁcant positive correlation between the plasma
LysoPS level and the plasma serotonin concentration not only in ACS,
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relation with PS-PLA1 (Fig. 4C). Actually, when we stimulated washed
platelets (which do not contain PS-PLA1) with thrombin, we observed
that LysoPS as well as other glycerol–lysophospholipids were secreted
(data not shown). Further basic studies are needed to elucidate the
source of LysoPS.
Investigation of the source of LysoPS is important for elucidating the
pathogenesis of atherosclerosis. Although the roles of LysoPS, especially
in the ﬁeld of atherosclerotic and thrombotic diseases, remain to be fully
elucidated at present, we recently reported that the dual actions of LysoPS
on macrophages may have a role in the pathogenesis of atherosclerotic
diseases; LysoPS promotes foamcell formation,while it attenuates the ex-
pressions of inﬂammatory mediators [34]. Reportedly, LysoPS exerts sev-
eral biological actions on the blood cells; it causes degranulation of mast
cells [35,36], suppression of T lymphocyte proliferation [37], and the en-
gulfment of apoptotic cells bymacrophages [38,39]. Moreover, the recep-
tor for LysoPS has recently been identiﬁed [3,40], which is considered as a
new pharmacological target in various ﬁelds. Thus, in view of the emerg-
ing importance of LysoPS, further investigation of the association between
the plasma levels of serotonin and LysoPS will be important.
The main limitation of this study is that we could not measure PF-4
or β-TG, well-known biomarkers for platelet activation other than sero-
tonin, since we prepared the samples without the special anti-platelet
cocktail CTAD (needed for the plasma sampling for the assay of these
two markers) and were concerned our samples might not be suitable
for themeasurement of PF-4 orβ-TG. Although serotonin ismore hardly
to increase ex vivo, i.e., after venipuncture, compared with PF-4 or β-TG
[20], the determinant factors for the plasma serotonin are not only the
secretion fromactivated platelet, but also theproduction by enterochro-
mafﬁn cells in intestine and theuptake of serotonin byplatelets and sev-
eral pathological states of subjects other than platelet activation such as
depression and use of selective serotonin reuptake inhibitor might
somehow inﬂuence the plasma serotonin level. Therefore, we cannot
deny the possibility that LysoPS derived from the other sources than
platelets, for example apoptotic endothelial cells generated in ACS. Fur-
ther studies are needed utilizing the speciﬁc biomarkers for platelet ac-
tivation, such as PF-4 or β-TG, to demonstrate the involvement of
platelet activation in the source of glycerol–LPLs in vivo.
Another limitation is that we measured the biomarkers such as
PS-PLA1 and glycerol–LPLs in the blood samples taken from the arterial
sheaths, while the venous blood samples are ordinarily utilized for the
similar clinical studies. Although we measured these biomarkers using
the identical blood samples to directly compare related parameters to
obtain mechanistic insights into the metabolism of glycerol–LPLs
in vivo, the possibility of this sampling difference affecting the data
cannot be ruled out. Furthermore, the concentrations of biomarkers
such as glycerol–LPLs and serotonin in the peripheral blood samples
may not represent the exact concentrations in the local lesions, where
the pathological events are occurring. Therefore, LysoPS on the surface
of platelets, for example, might be more reliable markers for platelet
activation than plasma LysoPS.
In summary, we found the existence of a speciﬁc positive correlation
between the plasma levels of serotonin and LysoPS, a newly reported
important lipid mediator. LysoPS production might be related to strong
platelet activation,which caused serotonin to be released extracellularly
from the cells.
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